Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Vast numbers of domestic violence incidents are attended by the police each year and recorded in Australia as both structured quantitative data and unstructured free text in the WebCOPS - a web-based interface for the Computerised Operational Policing System - database. The wealth of information in WebCOPS regarding the victim’s and person of interest’s (POI) incident details, particularly with respect to the unstructured text (Domestic Violence (DV) event narratives), remains widely untapped. Objective: In this paper we explore whether text mining can automatically identify mental health disorders from this unstructured text. Methods: We used a training set of 200 DV recorded events to design a knowledge-driven approach based on lexical patterns in text suggesting mental health disorders for POIs and victims. Results: The precision returned from an evaluation set of 100 DV events was 97.5% and 87.1% for mental health disorders related to POIs and victims respectively. After applying our approach to a large-scale corpus of almost half a million DV events, we observed that 77,995 events (16%) mentioned mental health disorders, with 77% of those linked to POIs versus 16% for the victims and 6% for both. Depression was observed to be the most prevalent mental health disorder for both victims (22%; 3,258) and POIs (19%; 8,918), followed by alcohol abuse for POIs (12%; 5,829) and various anxiety disorders for victims (11%; 1,671). Conclusions: The results suggest that text mining can automatically extract targeted information from domestic violence police recorded events to support further public health research.
Introduction Considerable evidence supports an association between poor impulse control (impulsivity) and violent crime. Furthermore, impulsivity and aggression has been associated with reduced levels of serotonergic activity in the brain. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants that aim to regulate brain serotonin concentrations. Several small studies in psychiatric populations have administered SSRIs to impulsive–aggressive individuals, resulting in reduced impulsivity, anger, aggression and depression. However, no clinical trial has been undertaken in a criminal justice population. This protocol describes the design and implementation of the first systematic study of the potential benefits of SSRIs in impulsive–violent offenders who are at high risk of reoffending. Methods and analysis A randomised, double-blinded, multicentre trial to test the clinical efficacy of an SSRI, sertraline hydrochloride, compared with placebo on recidivism and behavioural measures (including impulsivity, anger, aggression, depression and self-reported offending) over 12 months. 460 participants with histories of violence and screening positive for impulsivity are recruited at several local courts and correctional service offices in New South Wales, Australia. Ethics and dissemination Results will be submitted for publication in a peer-reviewed journal. Possible implications of the effectiveness of this pharmacological intervention include economic benefits of reducing prison costs and societal benefits of improving safety. This study has received ethical approval from the University of New South Wales, Aboriginal Health & Medical Research Council, Corrective Services NSW and the NSW Justice Health and Forensic Mental Health Network. Trial registration number ACTRN12613000442707.
Biological studies suggest serotonin modulation via selective serotonin reuptake inhibitors (SSRIs) might reduce impulsive violence, however, robust evidence in offender populations is limited. We aimed to determine whether sertraline reduces violent reoffending compared with placebo in highly impulsive men with recurrent violent offending. We conducted a double-blind, placebo-controlled, randomised clinical trial in community settings in New South Wales, Australia. Eligible participants were men aged 18 years or older with ≥2 prior violent convictions and a Barratt Impulsiveness Scale score ≥70. Following a 4-week single-blind active run-in phase with sertraline, participants were randomly assigned (1:1, minimization stratified by key factors) to receive oral sertraline (100 mg daily) or matching placebo for 12 months. The primary outcome was the first convicted violent offence within 12 months, assessed via linkage to the state Reoffending Database. The primary analysis followed the intention-to-treat principle. The trial is registered with ANZCTR (ACTRN12613000442707) and is closed to new participants. Between October 28, 2013, and July 13, 2021, 630 eligible men were randomly assigned: 319 to sertraline and 311 to placebo. By 12 months, only 204 participants remained engaged with the study. All participants were included in the primary analysis. A primary outcome event (violent offence within 12 months) occurred in 72 (22.6%) of 319 participants assigned sertraline and 70 (22.5%) of 311 assigned placebo (Relative Risk 1.00, 95% CI 0.75–1.34; p = 0.99). Serious adverse events occurred in 22 (6.9%) participants receiving sertraline and 29 (9.3%) receiving placebo. Sertraline did not significantly reduce the risk of violent reoffending compared with placebo. Post-hoc analyses suggested a possible selective effect on domestic violence offending. Initial funding for the ReINVEST trial was provided from an Australian National Health and Medical Research Council partnership grant No. 533559. From 2018, subsequent funding was provided by the 10.13039/501100025174 NSW Department of Communities and Justice .
5 April 2019 in Journal of Medical Internet Research
Preventing dropout (attrition) from clinical trials is vital for improving study validity. Dropout is particularly important in justice-involved populations as they can be very challenging to engage and recruit in the first instance. This study identifies factors associated with dropout in a double-blind, placebo-controlled randomised control trial of a selective serotonin reuptake inhibitor (SSRI) aimed at reducing reoffending in highly impulsive men with histories of violent offending. Age, education, social support, psychiatric history, and length of previous incarceration were identified as factors that predict attrition. These findings are consistent with previous research examining variables associated with attrition in clinical trials for community and offender populations. We also explored referral source and treatment allocation as attrition predictors. Although neither significantly predicted attrition, we identified that there are discernible differences in the median time to attrition among the referral source subgroups. Understanding factors that predict treatment completion and attrition will allow researchers to identify participants for whom additional provisions may optimise retention and inform development of targeted interventions.
Background: Deficits in central serotonergic function have been implicated in impulsive aggression; however, pharmacological evidence is constrained by small samples and the absence of real-world behavioural outcomes. We examined clinical and behavioural changes during single-blind sertraline treatment and evaluated treatment effects during the randomised phase of the ReINVEST trial.Methods: Secondary analysis of a randomised, double-blind, placebo-controlled trial conducted across 15 community sites in New South Wales, Australia (2013–2020). Men aged ≥18 years with ≥2 prior violent offence convictions and Barratt Impulsiveness Scale scores ≥70 completed a 4-week single-blind sertraline run-in before randomisation to sertraline 100 mg daily or matching placebo (n=319 vs n=311). Outcomes included depressive symptoms, psychological distress, impulsivity, anger expression and control, aggression, and health-related quality of life. Run-in changes were estimated using paired t-tests and randomised-phase treatment effects were estimated using analysis of covariance.Results: During run-in (n=796), participants demonstrated improvements in depression, psychological distress, impulsivity, aggression, and most anger domains. In the randomised phase, sertraline was associated with reductions in depressive symptoms (adjusted mean difference, -1.23; 95% CI, -2.36 to -0.09; P=0.035) and state anger (-1.14; 95% CI, -2.26 to -0.02; P=0.047).Conclusion: Sertraline produced broad symptomatic improvements during the run-in phase and selective reductions in depressive symptoms and state anger during the randomised phase. These findings suggest that sertraline's therapeutic action in impulsive violent offenders may be specific to affective reactivity and support further investigation of affect-mediated pathways linking pharmacotherapy to violence reduction.